drugset / Trial / NCT00374660
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
Timeline
- Start
- 2003-06
- Primary completion
- 2007-04
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 40 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 50 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 60 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 70 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 80 mg/m2 | — |
| Subject | irofulven | Small molecule | 0.3 mg/kg | — |
| Subject | irofulven | Small molecule | 0.4 mg/kg | — |